Related Experiment Videos
Chemoprophylaxis of recurrent otitis media using trimethoprim/sulfamethoxazole
Insights
Daily trimethoprim/sulfamethoxazole (TMP/SMX) effectively prevented recurrent acute otitis media (RAOM) in high-risk children. Prophylactic TMP/SMX for six months resulted in zero RAOM recurrences compared to eight in the control group.
Area of Science:
- Pediatrics
- Infectious Diseases
- Pharmacology
Background:
- Recurrent acute otitis media (RAOM) poses a significant health burden in pediatric populations.
- Identifying effective preventive strategies for RAOM in high-risk children is crucial.
Purpose of the Study:
- To evaluate the efficacy of daily trimethoprim/sulfamethoxazole (TMP/SMX) in preventing RAOM.
- To assess the safety and effectiveness of TMP/SMX prophylaxis in a high-risk pediatric cohort.
Main Methods:
- A prospective study involving 21 ambulatory pediatric patients divided into a study group (n=10) and a control group (n=11).
- The study group received daily TMP/SMX prophylaxis for six months, while the control group received acute treatment only.
- Statistical analysis included Fischer's exact test and chi-square with Yates's correction factor.
Main Results:
- The TMP/SMX prophylaxis group experienced zero recurrences of RAOM.
- The control group experienced eight recurrences of RAOM (one per child).
- The difference in recurrence rates was statistically significant (p < 0.005).
Conclusions:
- Daily TMP/SMX administration is a safe and effective prophylactic treatment for RAOM in high-risk pediatric patients.
- A six-month course of TMP/SMX significantly reduces RAOM recurrence.
- This prophylactic approach offers a viable strategy for managing RAOM in susceptible children.
Abstract:
This study was undertaken during the late fall, winter, and early spring months to determine the efficacy of daily trimethoprim/sulfamethoxazole (TMP/SMX) administration in the prevention of recurrent acute otitis media (RAOM) in a specific high-risk pediatric population. Twenty-one ambulatory patients, 10 in the study group and 11 in the control group, were selected from a medical university clinic and a local private practice. The study group receiving prophylactic therapy for six months suffered no recurrences, as compared with eight children suffering one recurrence each in the control group that was treated only acutely. The results were significant at p less than 0.005 with df = 1, determined by the Fischer's exact test and the chi-square method using Yates's correction factor. These data indicated that a mean dose of TMP/SMX 6.8/34 mg/kg/d divided into twice daily doses and given for six months was safe and effective in controlling RAOM infections in a high-risk pediatric population.